Andrew Kruse

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.